Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies

Li, Mengdi; Zhang, Yusheng; Zhang, Wenzhe; Sun, Jinlei; Li, Rui; Zhou, Pan; Zhang, Panpan; Liu, Shengyun

doi:10.3389/fimmu.2023.1169057

Cited by 3 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have validated the involvement of interferons in the pathogenesis of SSc [21,48,49]. Furthermore, a substantial body of evidence has established interferons as highly pleiotropic cytokines that play a pathogenetic role in diseases such as systemic lupus erythematosus, rheumatoid arthritis, idiopathic inflammatory myositis, and systemic sclerosis [50][51][52][53][54][55]. The activity of interferons is precisely regulated by interferon regulatory factors (IRFs).…”

Section: The Interferon Regulatory Factor Genesmentioning

confidence: 99%

Immunogenetics of Systemic Sclerosis

Gumkowska-Sroka,

Kotyla,

Kotyla

2024

Genes

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a rare autoimmune connective tissue disorder characterized by massive fibrosis, vascular damage, and immune imbalance. Advances in rheumatology and immunology over the past two decades have led to a redefinition of systemic sclerosis, shifting from its initial perception as primarily a “hyperfibrotic” state towards a recognition of systemic sclerosis as an immune-mediated disease. Consequently, the search for genetic markers has transitioned from focusing on fibrotic mechanisms to exploring immune regulatory pathways. Immunogenetics, an emerging field at the intersection of immunology, molecular biology, and genetics has provided valuable insights into inherited factors that influence immunity. Data from genetic studies conducted thus far indicate that alterations in genetic messages can significantly impact disease risk and progression. While certain genetic variations may confer protective effects, others may exacerbate disease susceptibility. This paper presents a comprehensive review of the most relevant genetic changes that influence both the risk and course of systemic sclerosis. Special emphasis is placed on factors regulating the immune response, recognizing their pivotal role in the pathogenesis of the disease.

show abstract

Section: The Interferon Regulatory Factor Genesmentioning

confidence: 99%

Immunogenetics of Systemic Sclerosis

Gumkowska-Sroka,

Kotyla,

Kotyla

2024

Genes

View full text Add to dashboard Cite

show abstract

Novel B-cell subsets as potential biomarkers in idiopathic inflammatory myopathies: insights into disease pathogenesis and disease activity

Reyes-Huerta,

Mandujano-López,

Velásquez-Ortiz

et al. 2024

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Idiopathic inflammatory myopathies are a heterogeneous group of rare autoimmune disorders characterized by progressive muscle weakness and the histopathologic findings of inflammatory infiltrates in muscle tissue. Although their pathogenesis remains indefinite, the association of autoantibodies with clinical manifestations and the evidence of high effectiveness of depleting therapies suggest that B cells could be implicated. Therefore, we explored the landscape of peripheral B cells in this disease by multiparametric flow cytometry, finding significant numerical decreases in memory and double negative subsets, as well as an expansion of the naïve compartment relative to healthy controls, that contribute to defining disease-associated B cell subset signatures and correlating with different clinical features of patients. Additionally, we determined the potential value of these subsets as diagnostic biomarkers, thus positioning B cells as neglected key elements possibly participating in idiopathic inflammatory myopathies onset or development.

show abstract

Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies

Choi,

Satoh,

Fritzler

2023

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review This manuscript reviews recently published advances in the identification of autoimmune inflammatory myopathies (AIM)-specific and AIM-related autoantibodies considered of value in the workup of patients suspected of having AIM. Newer autoantibodies, developments, and advances in the methodology of testing, the gaps and pitfalls in using these assays as diagnostic biomarkers, and the importance of considering overlap diseases and unique clinical AIM phenotypes are discussed. Recent findings Summary The spectrum of autoantibodies and related biomarkers in AIM continues to expand. Many of these have clear clinical implications in regard to subsets and overlap conditions of AIM, associated malignancy and pathological findings.

show abstract

Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies

Cited by 3 publications

References 48 publications

Immunogenetics of Systemic Sclerosis

Immunogenetics of Systemic Sclerosis

Novel B-cell subsets as potential biomarkers in idiopathic inflammatory myopathies: insights into disease pathogenesis and disease activity

Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies

Contact Info

Product

Resources

About